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Introduction
Since thoracoscopic lobectomy was introduced in 1990s, it 
has been regarded as a useful surgical option for early-stage 
lung cancer because it could reduce operative morbidities 
as compared with open lobectomy. However, some patients 
still complain of severe acute pain after thoracoscopic 
lobectomy, and the incidence of chronic pain was reported 
up to 30% (1,2). Penetration of the chest wall by trocars, 
torque at trocar, and compression of the intercostal nerves 
have all been suggested to cause pain after thoracoscopic 
lobectomy (3,4). Current analgesic options for acute pain 
include thoracic epidural analgesia, intravenous patient-
controlled analgesia (iv-PCA), thoracic paravertebral block, 
and continuous paravertebral infusion (c-PVI) of local 
anesthetics. Among these methods, iv-PCA has been widely 
used because of its technical simplicity and relatively effective 
pain management (5). However, side effects such as sedation, 
nausea, and vomiting due to iv-PCA’s systemic delivery of 
analgesics preclude its continuous use. In contrast, c-PVI 
of local anesthetics thorough a catheter below the parietal 
pleura has been known to reduce side effects of iv-PCA and 
effectively control postoperative pain (6). Although c-PVI 
could provide effective pain relief in comparison with iv-PCA 
with better side-effects profile in patients who underwent 
open thoracotomy (7-11), only a few existing studies 
have compared their analgesic effects after thoracoscopic 
lobectomy (6,12,13). Therefore, our study aimed to 
investigate the effectiveness of c-PVI as compared with that 
of iv-PCA after thoracoscopic lobectomy for lung cancer.
Methods
This prospective randomized comparative study was 
approved by the Institutional Review Board and registered 
at clinicaltrials.gov (NCT01703351). Patients who were 
either diagnosed or suspected with early lung cancer 
(clinical stage T1–2aN0M0), who were fit to thoracoscopic 
lobectomy, and who signed the informed consent were 
eligible. Permission was obtained from every patient after 
providing detailed information about the study. After all 
trocars were inserted, the patient was randomly assigned 
to either the c-PVI or the iv-PCA group using computer-
generated random numbers. Exclusion criteria included 
age younger than 18 years or older than 75 years, history 
of thoracic trauma or previous thoracic operation, chest 
pain for other reasons, severe pleural adhesion found at 
the time of operation, conversion to thoracotomy, and any 
complication that leads to intensive care unit admission. 
Chronic pain assessment was not conducted in patients who 
received repetitive chemical pleurodesis for air leakage, 
received adjuvant chemotherapy and/or radiation therapy, 
or refused the follow-up study after the operation.
Surgery
Thoracoscopic lobectomy with hilar and mediastinal lymph 
node dissection were performed with one utility incision and 
three ports. About 6 cm of utility incision was made at the 4th 
intercostal space (ICS) on the mid-axillary line level. A wound 
protector was applied without any rib spreader. The 12-mm 
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trocars were placed at the 6th ICS on the anterior axillary line 
level and at the 7th ICS on the midaxillary line level. A 5-mm 
trocar was placed at the 5th ICS on the posterior axillary line 
level. Standard postoperative care was provided, and a chest 
tube was removed when there was no air leakage and the 
amount of drainage was less than 200 mL/day. Patients were 
discharged the day after tube removal.
Analgesia delivery
In the c-PVI group, a catheter with several side holes (On-
Q system®; I-flow Corp, Lake Forest, CA, USA) was placed 
by a surgeon under thoracoscopic guidance at the end of 
operation. An introducer was inserted percutaneously 2 cm 
away from the vertebra on the 9th ICS and placed beneath 
the parietal pleura. The introducer was advanced up to the 
level of the 3rd ICS with caution to prevent any tearing on 
the parietal pleura. The introducer was removed after placing 
a catheter through it. After surgery, 0.5% ropivacaine was 
infused and maintained for 60 hours at a rate of 5 mL/hour. 
In the iv-PCA group, a patient-controlled infusion pump 
(Accufuser Plus, Wooyoung Medical Co., Ltd. Korea) was 
applied intravenously at the end of operation. It consisted of 
fentanyl 450–1,600 µg, nefopam 160 mg, and ramosetron 0.6 
mg and was maintained for 60 hours at a rate of 5 mL/hour. 
Fentanyl dose was adjusted according to the patient’s body 
weight. When the patients felt severe pain, they were allowed 
to press the button to infuse 0.5 mL of the anesthetics.
In both groups, two tablets of Ultracet® (acetaminophen 
650 mg plus tramadol 75 mg; Korea Janssen Pharmaceuticals, 
Inc., Seoul, Korea) were given orally three times a day. If 
the oral agent (Ultracet®) seemed ineffective in controlling 
postoperative pain, it was replaced by two capsules of Mypol® 
(codeine phosphate 10 mg plus ibuprofen 200 mg; Sungwon 
Adcock Pharm, Seoul, Korea). When a patient complained 
of pain despite the above-mentioned methods, 25 mg of 
intramuscular pethidine or 5 mg of oral oxycodone was 
provided. The oral agent was maintained for 2 weeks after 
discharge.
Acute pain assessment
Acute pain was assessed by a visual analogue scale (VAS; 
0, no pain; 10, worst pain imaginable). VAS score was 
measured at rest in the evening of the operation day. Over 
the next 4 days, VAS score was recorded three times a day 
both at rest and on coughing. The highest VAS score of 
each day was used for further analysis and categorized as 
mild (VAS 0–2), moderate (VAS 3–5), and severe (VAS 
6–10). Opioid dose, calculated as equivalent morphine 
dose (14), was also recorded during the first 4 days after 
operation. Pethidine 25 mg, fentanyl 1 mg, one capsule 
of Mypol®, and oxycodone 5 mg were substituted with 
morphine 3.3, 10, 0.8, and 10 mg, respectively.
Chronic pain and neuropathic pain assessment 
(quantitative sensory test)
Chronic pain was assessed by VAS at every follow-up. In 
addition, the item of “chest pain” in the quality of life (QoL) 
questionnaire was also used to identify mild chronic pain. 
Quantitative sensory testing (QST) was used to evaluate 
chronic neuropathic pain. QST is a non-invasive method 
for assessing peripheral nervous system disorder. We tested 
sensory detection threshold to touch, pressure, warmth, 
coolness as well as hot and cold pain at the outpatient 
clinic on 6, 12, and 24 weeks after surgery. Mapping of 
cool allodynia was also performed. The non-operated side 
forearm was tested first for reference, and then the non-
operated side chest and operated chest were tested. On the 
operated chest, testing was done 2 cm anterior to the utility 
incision and at the chest tube site. Among the two values 
obtained from both sites, the more abnormal value was 
considered representative of the operated chest.
Tactile detection threshold and tactile pain threshold 
were assessed by Electronic Von Frey filament (IITC Inc., 
USA) using the method of levels (15). Thermal assessments 
were performed by the TSA-II-NeuroSensory Analyzer 
(Medoc Ltd., Israel) and included warm detection threshold 
(WDT), cool detection threshold (CDT), heat pain 
threshold (HPT), and cold pain threshold (CPT). A baseline 
temperature of 32 ℃ was applied; then, the temperature 
was changed at 1 ℃ per second. The temperature range was 
0–50 ℃. Finally, thermal sensitivities were tested among 
QST. Mapping of cool allodynia was performed around 
the surgical scar using a cool metal instrument at 10 ℃. 
Mapping started from the outside and radially moved 
toward the scar at 2-cm intervals. Areas with cool allodynia 
were marked with a marking pen, and the marks were 
connected to form an outline of the outer margins. This 
line was traced onto a translucent sheet and scanned and 
analyzed using ImageJ (http://rsb.info.nih.gov/ij/).
QoL 
QoL was assessed using the European Organization 
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for Research and Treatment of Cancer quality of life 
questionnaire (EORTC QLQ-C30) and the lung cancer 
module (LC13). Every patient filled out the questionnaire 
before surgery and at 12 and 24 weeks after the operation. 
EORTC QLQ-C30 consisted of 30 items (6 functional 
scales and 9 symptom scales). LC13 consisted of 13 items 
(10 symptom scales). All scales were scored by the EORTC 
QLQ-C30 scoring manual (16), and the scores ranged from 
0 to 100. A high score in global health status represents 
a high QoL. A high score in functional scale represents a 
high level of functioning. A high score in symptom scale 
represents a high level of symptoms or problems.
Statistics
To calculate the required sample size, we took into account the 
results of a previous study that had a similar clinical setting (17). 
A power analysis indicated that 41 patients were required in 
each group to detect a difference of 1 point in the VAS score 
[0–10] and 30-mg cumulative dose of opioids, with a type I 
error of 0.05 and power of 80%. A total of 96 patients were to 
be enrolled considering a 15% withdrawal rate.
The two groups were compared using Student’s t-test for 
continuous variables and Fisher’s exact tests for categorical 
variables. Continuous data are expressed as mean ± standard 
deviation, whereas categorical variables are expressed 
as counts and percentages. Tactile assessment data were 
analyzed using Mann-Whitney U test, whereas thermal 
assessment data and sensory mapping data were analyzed 
using Student’s t-tests. The results of the EORTC QLQ 
were grouped based on scales (global QoL, functional scales, 
symptom scales, and lung module function scales) and then 
compared with the Student’s t-test. A P value less than 0.05 
was considered statistically significant. All statistical analyses 
were performed using the SPSS version 21 statistical software 
program (SPSS Inc., Chicago, IL, USA).
Results
Eighty-four patients were enrolled in this study between 
October 2012 and August 2015. The study was closed 
earlier before the enrollment of 96 patients because of 
slow accrual. At the time of the operation, 5 patients 
were excluded from randomization due to severe pleural 
adhesion. Hence, only 79 patients were randomized to the 
c-PCA group (n=41) or to the iv-PCA group (n=38).
There were no significant differences in the baseline 
characteristics between the two groups (Table 1). All patients 
underwent the planned procedure by thoracoscopy, and 
there was no incidence of reoperation or other serious 
complications that required intensive care unit admission.
Acute pain assessment and amount of opioid used
Acute pain at rest or coughing was not significantly different 
between the two groups throughout 4 postoperative days 
(Table 2). Although the amount of additional opioids was 
not different between the two groups, the total amount of 
administered opioids was significantly lower in the c-PVI 
group than in the iv-PCA group when the fentanyl in the 
PCA pump was added in the calculation. The incidence of 
opioid-related side effects such as dizziness, constipation, 
pruritus, or nausea was similar in both groups (Table 3). 
However, the incidence of severe side effects leading to 
discontinuation of analgesics was significantly lower in the 
c-PVI group than in the iv-PCA group.
Table 1 Patients’ clinical characteristics
Variable c-PVI (n=41) iv-PCA (n=38) P value
Age (years) 58±8 59±8 0.793
Male 21 (51.2) 21 (55.3) 0.822
BMI (kg/m
2
) 22.9±5.2 24.1±3.5 0.318
FVC (%) 98±10 104±15 0.127
FEV1 (%) 103±14 109±16 0.171
DLCO (mL/min/mmHg) 114±24 110±19 0.465
Smoking 18 (43.9) 17 (44.7) >0.999
Comorbidity* 17 (41.5) 15 (39.5) >0.999
Stage IA/IB 32/9 32/6 0.572
Blood loss (mL) 58±57 92±88 0.067
Operation time (min) 113±18 125±34 0.095
Chest tube stay (days) 3.6±1.3 3.7±1.3 0.746
Chemical pleurodesis 10 (24.4) 7 (18.4) 0.591
Hospital stay (days) 4.9±1.4 5.0±1.3 0.774
Values are presented as mean ± standard deviation or n (%). 
*, comorbidity included hypertension, diabetes, hepatitis, 
cancer, or cerebrovascular accident history. c-PVI, continuous 
paravertebral infusion; iv-PCA, intravenous patient-controlled 
analgesia; BMI, body mass index; FVC, forced vital capacity; 
FEV1, forced expiratory volume in one second; DLCO, diffusing 
capacity of carbon monoxide.
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Table 2 Maximum acute pain based on treatment at different time points
Variables Pain
Resting Coughing
c-PVI (n=41) iv-PCA (n=38) P value c-PVI (n=41) iv-PCA (n=38) P value
POD0 Mild 1 [2] 0 [0] 0.772
Moderate 8 [20] 6 [16]
Severe 32 [78] 32 [84]
POD1 Mild 6 [15] 9 [24] 0.299 0 [0] 1 [3] 0.465
Moderate 15 [37] 17 [45] 6 [15] 8 [21]
Severe 20 [49] 12 [32] 35 [85] 29 [76]
POD2 Mild 11 [27] 12 [32] 0.711 2 [5] 1 [3] 0.059
Moderate 16 [39] 16 [43] 13 [32] 21 [57]
Severe 14 [34] 9 [24] 26 [63] 15 [41]
POD3 Mild 18 [44] 21 [55] 0.264 6 [15] 6 [16] 0.380
Moderate 16 [39] 15 [40] 18 [44] 22 [58]
Severe 7 [17] 2 [5] 17 [42] 10 [26]
POD4 Mild 25 [62] 26 [70] 0.181 10 [25] 13 [35] 0.189
Moderate 11 [28] 11 [30] 19 [47] 20 [54]
Severe 4 [10] 0 [0] 11 [28] 4 [11]
Values are presented as n [%]. c-PVI, continuous paravertebral infusion; iv-PCA, intravenous patient-controlled analgesia; POD1, 
postoperative day 1; POD2, postoperative day 2; POD3, postoperative day 3; POD4, postoperative day 4.
Table 3 Total dose of opioid and incidence of opioid-related side effects
Variables c-PVI (n=41) iv-PCA (n=38) P value
Additional opioid dose (mg) 14.0±11.7 10.5±10.9 0.180
Total opioid dose including fentanyl in PCA (mg) 14.0±11.7 20.8±10.4 0.008
Side effects
Dizziness 4 (9.8) 8 (21.1) 0.215
Constipation 5 (12.2) 11 (28.9) 0.093
Pruritus 1 (2.4) 4 (10.5) 0.190
Nausea 8 (19.5) 9 (23.7) 0.786
Discontinuation of analgesics 1 (2.4) 8 (21.1) 0.012
Values are presented as n (%). c-PVI, continuous paravertebral infusion; iv-PCA, intravenous patient-controlled analgesia.
Assessment of chronic pain and QoL
During follow-up, 12 patients (c-PVI, n=7; iv-PCA, n=5) 
declined to continue joining the study. In 8 patients who 
received adjuvant chemotherapy for unexpected nodal metastasis 
(c-PVI, n=7; iv-PCA, n=1), assessment of chronic pain and QoL 
were not indicated. As a result, chronic pain and QoL could 
only be assessed in 59 patients (c-PVI, n=27; iv-PCA, n=32).
Chronic pain based on VAS score was reduced over time, 
and only 1 patient complained of chronic pain at the end 
of follow-up (24 weeks after surgery). However, when the 
EORTC QLQ-LC13 questionnaire was given, 25 patients 
(42%) answered that they felt mild pain in their response 
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to “chest pain” item in the questionnaire (Table 4), although 
there was no statistical difference between the two groups.
All patients completed the EORTC QLQ-C30-LC13 
questionnaire during the follow-up period. No significant 
difference was observed between the two groups, but the 
global QoL was significantly higher in the PCA group at 
12 weeks when broken down into separate scales (Table S1).
Neuropathic pain
The results of the tactile and thermal assessment are shown 
in Table S2 and Figure 1. On the contralateral forearm and 
non-operated chest, there were no significant differences 
in patients’ responses to tactile and thermal stimulation 
between the two groups. After operation, the thresholds 
for tactile and thermal stimulation significantly increased 
on the operated chest compared with those on the non-
operated chest. The difference decreased over the course 
of time. However, no significant differences were observed 
between the two groups at each follow-up examination.
During sensory mapping, hypoesthesia to coolness was 
found in 54 (91.5%) patients at 6 weeks, 50 (84.7%) at 
12 weeks, and 39 (66.1%) at 24 weeks. The total area of 
hypoesthesia showed no significant difference between the 
groups at each follow-up examination (Figure 2).
Post hoc analysis
We also performed post hoc analysis to investigate the 
characteristics of patients with chronic pain. Patients 
who reported chronic pain on the QoL questionnaire 
were compared with those who did not. Baseline patient 
characteristics were not significantly different between 
the two groups. Acute pain was significantly worse in the 
chronic pain group on postoperative day 3, at both resting 
and coughing states (Table 5). The results of QST did not 
show significant differences between the groups (Table 6).
Discussion
Our study demonstrated that c-PVI of local anesthetics 
was as effective as iv-PCA in the management of acute 
and chronic pain while the total amount of opioid 
administration and the incidence of serious side effects were 
significantly reduced.
When comparing acute pain profiles between the two 
groups, the highest scores of pain at rest or coughing were 
used and divided into mild, moderate, and severe levels of 
pain, as generally accepted in previous research (18,19). 
This simple categorization is relevant in helping physicians 
make clinical decisions. For example, when patients 
continuously experience severe pain before discharge, oral 
analgesics could be increased. If this was insufficient, PCA 
should be reinitiated, with discharge delayed.
Although it has been well known that c-PVI can provide 
pain relief that is comparable to traditional iv-PCA with 
better side-effects profile after open thoracotomy (7-11), 
only a few existing studies have compared the analgesic 
effects of iv-PCA and c-PVI after thoracoscopic lobectomy 
(6,12,13). Similar to two reports from Asia (6,12), the 
current study demonstrated that c-PVI of local anesthetics 
could mitigate acute postoperative pain as effectively as iv-
PCA. These results were different from those provided 
by another report (13), which showed a superiority in the 
analgesic effect of c-PVI using percutaneous technique. 
In our study, the infusion catheter was inserted beneath 
the parietal pleura under direct thoracoscopic vision. 
Although catheter insertion under magnified thoracoscopic 
guidance is more helpful, as compared to the percutaneous 
technique, there have been concerns about parietal pleura 
tearing, which could cause leakage of local anesthetics 
into the pleural cavity, leading to insufficient analgesic 
effect (6). Although the cases with severe pleural adhesion 
were excluded from our study, 24% of patients with mild 
to moderate pleural adhesion were enrolled in the c-PVI 
group. We speculated that there might be a higher chance 
of small pleural tearing during adhesiolysis, which could be 
Table 4 Chronic pain (patients who reported “chest pain” on 
EORTC QLQ-LC13 questionnaire)
Variables c-PVI (n=27) iv-PCA (n=32) P value
Before operation 8 [30] 9 [28] 0.899
Postoperative
2 weeks 19 [70] 25 [78] 0.496
6 weeks 20 [74] 21 [66] 0.483
12 weeks 18 [67] 17 [53] 0.291
24 weeks 15 [56] 10 [31] 0.060
Values are presented as n [%]. Chronic pain was assessed in 
59 patients excluding patients who declined continuation of 
enrollment or received adjuvant chemotherapy or repetitive 
pleurodesis. EORTC QLQ-LC13, European Organization for 
Research and Treatment of Cancer quality of life and lung 
cancer module questionnaire; c-PVI, continuous paravertebral 
infusion; iv-PCA, intravenous patient-controlled analgesia.
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Figure 1 Serial changes in quantitative sensory test for the c-PVI (black box) and iv-PCA groups (open box) during follow-up. The gray box 
represents values from the non-operated chest. There was no significant difference between groups. Data are expressed as box plot. Median, 
horizontal line; interquartile range, box; range, whiskers; c-PVI, continuous paravertebral infusion; iv-PCA, intravenous patient-controlled 
analgesia; TDT, tactile detection threshold; TPT, tactile pain threshold; WDT, warm detection threshold; CDT, cold detection threshold; 
HPT, heat pain threshold; CPT, cold pain threshold.
a possible reason for the relatively higher VAS score in the 
c-PVI group.
This study showed that severe or repetitive side effects 
leading to the discontinuation of analgesic infusion were 
statistically lower in the c-PVI group. It is likely to stem 
from the difference in the amount of opioid administration. 
Given that opioid exposure can put patients at risk for long-
term opioid use (20) or abuse (21), c-PVI could be a useful 
option to manage postoperative pain without increased risk 
of opioid abuse.
The incidence of chronic pain in this study is relatively 
higher compared with that (20–30%) reported in previous 
studies (1,22,23). The item of “chest pain” in the EORTC 
Q30 for QoL assessment, which has been associated with 
chronic post-surgical pain (24,25), was used to assess chronic 
pain in this study. There is a possibility that more patients 
with chronic pain could have been involved using the “chest 
item” item in EORTC Q30, since the questionnaire on the 
QoL represents any event of pain occurring over the past 1 
week, whereas the numeric pain rating scale or VAS in other 
studies showed any pain during the past 24 hours. When 
comparing the chronic pain group with the no chronic pain 
group, there was no difference in baseline characteristics. 
Pain intensity at resting and coughing on postoperative day 
3 when both c-PVI and iv-PCA were discontinued in most 
cases was highly associated with chronic pain. This result is 
similar with those in previous reports (22,25), which showed 
that pain intensity after thoracic operations correlated 
well with the occurrence of chronic pain. Therefore, 
we need to find the optimal pain management methods 
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after discontinuation of c-PVI or iv-PCA to decrease the 
incidence of chronic chest pain.
Chronic neuropathic pain is common after thoracic 
surgery. Similar to other studies (26-28), each item in our 
QST showed increased thresholds on the operated side 
as compared to the control side in all patients. However, 
no difference in quantitative sensory item was found 
between the chronic pain group and the no chronic pain 
group, unlike in other studies that showed increased 
thermal thresholds after breast cancer (26) as well as hernia 
repair (27) or increased tactile detection threshold after 
thoracoscopic lobectomy (28). This discrepancy between 
chronic pain and chronic neuropathic pain profiles might 
stem from the fact that the QST in this study, which mainly 
reflected the change in the thresholds of the intercostal 
nerve, could not represent chronic pain after thoracoscopic 
lobectomy and lymph node dissection that could have 
occurred from visceral stimulation causing sensitization of 
the central nervous system, thus leading to the development 
of somatic chronic pain via viscero-somatic convergent 
mechanism (29,30). This finding is consistent with that of 
a previous study (31), which demonstrated that only a half 
of chronic pain after thoracic surgery showed a neuropathic 
component.
Study limitations
A major limitation of this study was the slow accrual rate 
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Figure 2 Serial changes in area of hypoesthesia for the c-PVI (solid 
box) and iv-PCA groups (open box). There was no significant 
difference between groups. Data are expressed as box plot. Median, 
horizontal line; interquartile range, box; range, whiskers; c-PVI, 
continuous paravertebral infusion; iv-PCA, intravenous patient-
controlled analgesia.
Table 5 Maximum acute pain based on treatment at different time points in the group with or without chronic pain
Postoperative 
day
Pain
Resting, n [%] Coughing, n [%]
Chronic pain (−) (n=34) Chronic pain (+) (n=25) P value Chronic pain (−) (n=34) Chronic pain (+) (n=25) P value
0 Mild 3 [9] 1 [4] 0.608
Moderate 3 [9] 4 [16]
Severe 28 [82] 20 [80]
1 Mild 10 [29] 6 [24] 0.786 3 [9] 0 [0] 0.385
Moderate 12 [35] 8 [32] 4 [12] 4 [16]
Severe 12 [35] 11 [44] 27 [79] 21 [84]
2 Mild 19 [56] 10 [40] 0.483 5 [15] 2 [8] 0.616
Moderate 7 [21] 7 [28] 14 [41] 9 [36]
Severe 8 [23] 8 [32] 15 [44] 14 [56]
3 Mild 26 [76] 11 [44] 0.012 13 [38] 6 [24] 0.044
Moderate 8 [24] 11 [44] 15 [44] 7 [28]
Severe 0 [0] 3 [12] 6 [18] 12 [48]
4 Mild 30 [88] 18 [72] 0.243 19 [56] 11 [44] 0.433
Moderate 3 [9] 6 [24] 11 [32] 8 [32]
Severe 1 [3] 1 [4] 4 [12] 6 [24]
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Table 6 Results of quantitative sensory test in the group with or without chronic pain
Variables Chronic pain (−) (n=34) Chronic pain (+) (n=25) P value
TDT (mN)
6 weeks 3.9 (0.7–15.1) 5.9 (1.6–13.7) 0.419
12 weeks 1.6 (0.4–4.4) 3.9 (0.5–9.8) 0.279
24 weeks 0.7 (0.2–2.2) 0.7 (0.2–5.9) 0.969
TPT (mN)
6 weeks 254.9 (34.3–2,941.2) 784.3 (58.9–2,941.2) 0.276
12 weeks 39.2 (9.8–174.0) 19.6 (9.8–147.0) 0.975
24 weeks 19.6 (5.9–58.8) 13.7 (5.9–39.2) 0.369
WDT (℃)
6 weeks 39.8±5.3 41.0±6.1 0.521
12 weeks 39.2±5.1 39.8±4.9 0.720
24 weeks 38.6±4.0 38.1±3.6 0.735
CDT (℃)
6 weeks 23.9±8.6 18.2±10.5 0.091
12 weeks 25.7±6.1 19.0±12.4 0.080
24 weeks 26.8±2.9 25.6±4.1 0.385
HPT (℃)
6 weeks 46.8±3.1 46.4±3.3 0.718
12 weeks 46.4±3.0 46.1±2.8 0.793
24 weeks 47.0±3.0 45.7±3.5 0.320
CPT (℃)
6 weeks 10.4±9.9 11.1±7.2 0.819
12 weeks 13.7±9.1 14.0±8.7 0.925
24 weeks 14.5±8.6 13.9±9.8 0.868
Area of hypoesthesia (cm²)
6 weeks 161±114 197±104 0.222
12 weeks 96±90 130±87 0.152
24 weeks 44±58 54±65 0.557
Values are presented as median (interquartile range) or mean ± standard deviation. TDT, tactile detection threshold; TPT, tactile pain 
threshold; WDT, warm detection threshold; CDT, cold detection threshold; HPT, heat pain threshold; CPT, cold pain threshold.
and a study size smaller than anticipated. This weakened 
the analytic power of the study; therefore, subtle differences 
may not have been detected. We tried to evaluate the 
efficacy of c-PVI on various aspects. However, frequent 
visits and the time spent on conducting many neurological 
examinations were the major contributor to slow accrual and 
the decline during follow-up. Another limitation was the 
lack of confirmation on complete and accurate positioning 
of the c-PVI catheter because any catheter malpositioning 
or pleural leakage could affect the results. Nevertheless, 
this study is still meaningful in that it encompassed not only 
acute pain indices, but also chronic neuropathic pain and 
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QoL, thereby attempting to evaluate comprehensively the 
efficacy of c-PVI compared with iv-PCA.
In conclusion, this clinical trial showed that c-PVI was 
similar to iv-PCA in terms of providing acute pain relief 
and reducing chronic neuropathic pain after thoracoscopic 
lobectomy, with reduction of the repetitive side effects of 
opioids.
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Table S1 Self-reported quality of life (QOL) by EORTC QLQ-C30, -LC13
Variables
Baseline 12 weeks 24 weeks
On-Q (n=27) IV-PCA (n=32) P value On-Q (n=27) IV-PCA (n=32) P value On-Q (n=27) IV-PCA (n=32) P value
EORTC QLQ-C30
Global QOL 61.1±26.5 70.5±21.0 0.137 62.3±19.7 73.4±17.5 0.026 73.4±16.3 76.5±18.0 0.494
Functional scales 86.8±10.2 87.5±9.4 0.781 84.4±13.3 85.0±14.4 0.871 86.1±11.2 84.6±14.2 0.659
Symptom scales 18.0±8.9 16.9±6.3 0.606 17.8±12.4 15.9±11.1 0.558 12.8±8.7 14.2±13.2 0.651
LC 13
Symptom scales 22.0±11.3 17.8±10.5 0.153 18.5±11.3 14.0±10.5 0.119 13.2±7.5 11.2±9.8 0.394
After 24 weeks, no significant difference was found between the two groups. EORTC QLQ-C30, -LC13, European Organization for 
Research and Treatment of Cancer quality of life questionnaire, Core and Lung Cancer module.
Table S2 Results of quantitative sensory test (operated chest vs. non-operated chest) 
Variables Operated chest (n=59) Non-operated chest (n=59) P value
TDT (mN)
6 weeks 4.5 (0.6–13.7) 0.4 (0.1–0.7) <0.001
12 weeks 1.5 (0.4–5.9) 0.7 (0.2–1.6) <0.001
24 weeks 0.7 (0.2–3.9) 0.2 (0.1–0.7) <0.001
TPT (mN)
6 weeks 98.0 (19.6–980.3) 19.6 (9.8–58.8) 0.001
12 weeks 39.2 (9.8–147.0) 13.7 (5.9–19.6) <0.001
24 weeks 19.6 (5.9–58.8) 9.8 (5.9–19.6) 0.024
WDT (℃)
6 weeks 40.3±5.6 35.5±1.5 <0.001
12 weeks 39.4±5.0 35.6±1.8 <0.001
24 weeks 38.4±3.8 35.2±1.2 <0.001
CDT (℃)
6 weeks 21.4±9.7 28.1±2.4 <0.001
12 weeks 22.8±9.7 28.5±2.0 0.002
24 weeks 26.3±3.4 28.4±2.0 0.009
HPT (℃)
6 weeks 46.6±3.1 44.4±3.7 0.010
12 weeks 46.3±2.9 44.2±3.3 0.011
24 weeks 46.5±3.2 43.8±3.0 0.002
CPT (℃)
6 weeks 10.7±8.7 18.3±8.1 <0.001
12 weeks 13.8±8.8 18.2±9.0 0.053
24 weeks 14.2±8.8 19.7±8.5 0.021
TDT, tactile detection threshold; TPT, tactile pain threshold; WDT, warm detection threshold; CDT, cold detection threshold; HPT, heat pain 
threshold; CPT, cold pain threshold.
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